Pharmaceutics
(Apr 2023)
Characterization of Potent ABCG2 Inhibitor Derived from Chromone: From the Mechanism of Inhibition to Human Extracellular Vesicles for Drug Delivery
Glaucio Valdameri,
Diogo Henrique Kita,
Julia de Paula Dutra,
Diego Lima Gomes,
Arun Kumar Tonduru,
Thales Kronenberger,
Bruno Gavinho,
Izadora Volpato Rossi,
Mariana Mazetto de Carvalho,
Basile Pérès,
Ingrid Fatima Zattoni,
Fabiane Gomes de Moraes Rego,
Geraldo Picheth,
Rilton Alves de Freitas,
Antti Poso,
Suresh V. Ambudkar,
Marcel I. Ramirez,
Ahcène Boumendjel,
Vivian Rotuno Moure
Affiliations
Glaucio Valdameri
Graduate Program in Pharmaceutical Sciences, Laboratory of Cancer Drug Resistance, Federal University of Parana, Curitiba 80210-170, PR, Brazil
Diogo Henrique Kita
Graduate Program in Pharmaceutical Sciences, Laboratory of Cancer Drug Resistance, Federal University of Parana, Curitiba 80210-170, PR, Brazil
Julia de Paula Dutra
Graduate Program in Pharmaceutical Sciences, Laboratory of Cancer Drug Resistance, Federal University of Parana, Curitiba 80210-170, PR, Brazil
Diego Lima Gomes
Graduate Program in Pharmaceutical Sciences, Laboratory of Cancer Drug Resistance, Federal University of Parana, Curitiba 80210-170, PR, Brazil
Arun Kumar Tonduru
School of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, 70211 Kuopio, Finland
Thales Kronenberger
School of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, 70211 Kuopio, Finland
Bruno Gavinho
Microbiology, Parasitology and Pathology Program, Federal University of Parana, Curitiba 81530-000, PR, Brazil
Izadora Volpato Rossi
Cell and Molecular Biology Program, Federal University of Parana, Curitiba 81530-000, PR, Brazil
Mariana Mazetto de Carvalho
Biopol, Graduate Program in Pharmaceutical Sciences, Federal University of Parana, Curitiba 80210-170, PR, Brazil
Basile Pérès
Département de Pharmacochimie Moléculaire UMR 5063, Université Grenoble Alpes, 38041 Grenoble, France
Ingrid Fatima Zattoni
Graduate Program in Pharmaceutical Sciences, Laboratory of Cancer Drug Resistance, Federal University of Parana, Curitiba 80210-170, PR, Brazil
Fabiane Gomes de Moraes Rego
Graduate Program in Pharmaceutical Sciences, Federal University of Parana, Curitiba 80210-170, PR, Brazil
Geraldo Picheth
Graduate Program in Pharmaceutical Sciences, Federal University of Parana, Curitiba 80210-170, PR, Brazil
Rilton Alves de Freitas
Biopol, Graduate Program in Pharmaceutical Sciences, Federal University of Parana, Curitiba 80210-170, PR, Brazil
Antti Poso
School of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, 70211 Kuopio, Finland
Suresh V. Ambudkar
Laboratory of Cell Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-4256, USA
Marcel I. Ramirez
Laboratory of Cell Biology, Carlos Chagas Institute, Fiocruz, Curitiba 81310-020, PR, Brazil
Ahcène Boumendjel
Université Grenoble Alpes, INSERM, LRB, 38000 Grenoble, France
Vivian Rotuno Moure
Graduate Program in Pharmaceutical Sciences, Laboratory of Cancer Drug Resistance, Federal University of Parana, Curitiba 80210-170, PR, Brazil
DOI
https://doi.org/10.3390/pharmaceutics15041259
Journal volume & issue
Vol. 15,
no. 4
p.
1259
Abstract
Read online
Inhibition of ABC transporters is a promising approach to overcome multidrug resistance in cancer. Herein, we report the characterization of a potent ABCG2 inhibitor, namely, chromone 4a (C4a). Molecular docking and in vitro assays using ABCG2 and P-glycoprotein (P-gp) expressing membrane vesicles of insect cells revealed that C4a interacts with both transporters, while showing selectivity toward ABCG2 using cell-based transport assays. C4a inhibited the ABCG2-mediated efflux of different substrates and molecular dynamic simulations demonstrated that C4a binds in the Ko143-binding pocket. Liposomes and extracellular vesicles (EVs) of Giardia intestinalis and human blood were used to successfully bypass the poor water solubility and delivery of C4a as assessed by inhibition of the ABCG2 function. Human blood EVs also promoted delivery of the well-known P-gp inhibitor, elacridar. Here, for the first time, we demonstrated the potential use of plasma circulating EVs for drug delivery of hydrophobic drugs targeting membrane proteins.
Keywords
WeChat QR code
Close